← brief for 2026-09-16 · Slowing decline

Effectiveness of SGLT2 inhibitors in slowing chronic kidney disease progression and reducing mortality: a meta-analysis

Key takeaways

This meta-analysis of 12 large trials with over 40,000 people showed SGLT2 inhibitors reduced the risk of kidney failure, major heart problems, or death by about 25%. This strong evidence supports using these drugs to slow kidney decline in people with type 2 diabetes.

Who did this work

Sharma A (Harvard Medical School, Harvard University , , ,) · Sharma B (Gori Devi Girls College, University of Rajasthan , , ,) · Vamaraju D (Institute of Systems Science, National University of Singapore , ,) · Ajay A (Harvard Medical School, Harvard University , , ,)

Source

Paper · Europe PMC, CKD · 2026-09-15
https://europepmc.org/article/PMC/PMC13572723